• Sign in

  • Join for free
  • Donate Today!
  • We are Social
    • Facebook
    • Twitter
    • Instagram
    • YouTube
    • LinkedIn
  • Who
    we are
    • Who we are
    • Our Story
    • Rosie
    • Rosie’s Blog
    • Our Trustees
    • Our Patrons
  • What
    we do
  • Secondary
    Breast Cancer
    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Your Stories
    • Where to go for information
  • Get
    involved
    • Our Fundraisers
    • How to fundraise
    • Events
      • Fonthill Open Garden Party
      • Past Events
  • News
    • News
    • In the media
    • Video
    • Rosie’s Blog
  • Contact
Secondary1st
  • Donate Today!

Search

Login

Register
  • 020 8905 3955info@secondary1st.org.uk
0
Secondary1st
  • Menu
  • Who
    we are
    • Who we are
    • Our Story
    • Rosie
    • Rosie’s Blog
    • Our Trustees
    • Our Patrons
  • What
    we do
  • Secondary
    Breast Cancer
    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Your Stories
    • Where to go for information
  • Get
    involved
    • Our Fundraisers
    • How to fundraise
    • Volunteer
    • Events
      • Fonthill Open Garden Party
      • Past Events
  • News & Media
    • News
    • In the media
    • Video
    • Rosie’s Blog
  • Contact
  • Donate Today!
07June

Good Results From Parp Inhibitor Trial

Next
Previous
June 07, 2021
By cuco_admin_sec
0 Comment

A drug trial for Olaparib, also known as Lynparza, has shown good results for women with breast cancer who have faulty variants in BRCA1 or BRCA2 genes.  In the trial 85.9% of women given Olaparib for one year after the end of treatment showed no return of the cancer for three years, compared with77.1% of those given a placebo.  The results for metastatic breast cancer were similarly significant, with 87.5% for those on Olaparib and 80.4% for those on a placebo.  Olaparib is a PARP Inhibitor; Parp is short for Poly(ADP-ribose) polymerase, a protein which repairs DNA damage in cells.  Some cancer cells rely on PARP to keep their DNA healthy, including cancer cells with a change in one of the BRCA genes.  It is thought that Olaparib can stop PARP from repairing DNA  damage so that the cancer cells cannot repair themselves and die.  The trial was run by an international steering committee chaired by Professor Andrew Tutt who is Head of the Division of Breast Cancer Research and Director of the Breast Cancer Now Toby Robins Research Centre at the ICR and Guy’s Hospital King’s College London. He is a Clinician Scientist with the Laboratory and Clinical Trials programme, and a Consultant Clinical Oncologist looking after women with breast cancer. Professor Tutt came to the first Secondary1st Grant Presentation in 2017 and introduced Dr Claire Wells, who received our grant to fund a researcher in her team of scientists.

Categories: News
  • Search

  • Sign up for Newsletter

    * = required field
  • Categories

    • Event
    • Fundraising
    • In the media
    • News
    • Past Events
    • Rosie's blog
    • Uncategorised
    • Your Stories
  • Latest News

    • Walking the Wall

      June 09, 2022

    • A New Breast Cancer Drug

      June 09, 2022

    • Carol goes Ziplining at Eighty

      May 09, 2022

    • Lucy, Lara, Anoushka, Alexander, Theo, Elica and Emily Go Cycling

      May 09, 2022

  • Who We Are

    • Who we are
    • Our Story
    • Rosie
    • Rosie’s blog
    • Our Trustees
    • Our Patrons
  • What We Do

    • What we do
  • Secondary Breast Cancer

    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Where to go for information
  • Get Involved

    • How to fundraise
    • Our Fundraisers

© 2016 - 2022 Secondary First is a Company Limited by Guarantee. Registered in England and Wales No. 9920657. Registered Office: 1st Floor Healthaid House, Marlborough Hill, Harrow, HA1 1UD. It is a Registered Charity Number 1165614.
Site maintained by CuCo Creative.

  • Cookie Policy
  • Privacy Policy